Literature DB >> 25941024

Genetic Variability of AdeRS Two-Component System Associated with Tigecycline Resistance in XDR-Acinetobacter baumannii Isolates.

S Montaña1, E Vilacoba, G M Traglia, M Almuzara, M Pennini, A Fernández, A Sucari, D Centrón, M S Ramírez.   

Abstract

The emergence of tigecycline resistance has increased in the last years. Although tigecycline-resistant Acinetobacter baumannii isolates were described all over the world, few reports regarding the molecular basis of this resistance are available. It has been recognized that the overexpression of AdeABC efflux pump is related to the tigecycline-resistant phenotype. In 37 clinical A. baumannii isolates we first determined the tigecycline-resistant phenotype and then, within a selected group, we analyzed the sequence of the adeRS operon, which is involved in the expression of the AdeABC efflux pump. Nucleotide sequence analysis of adeR and adeS showed the presence of 5 and 16 alleles, respectively. These results expose a high genetic variability in both genes, the adeS gene being more susceptible to genetic variation. The presence of 2 AdeR and 2 AdeS new variants were reported. Two of the new AdeRS variants were present in the intermediate and the resistant tigecycline A. baumannii isolates, suggesting a putative role in the development of the observed phenotype. More studies need to be addressed to determine the role of the genetic variability observed in the adeRS operon.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25941024     DOI: 10.1007/s00284-015-0829-3

Source DB:  PubMed          Journal:  Curr Microbiol        ISSN: 0343-8651            Impact factor:   2.188


  23 in total

1.  In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.

Authors:  Paul G Higgins; Thamarai Schneiders; Axel Hamprecht; Harald Seifert
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Pan-PCR, a computational method for designing bacterium-typing assays based on whole-genome sequence data.

Authors:  Joy Y Yang; Shelise Brooks; Jennifer A Meyer; Robert R Blakesley; Adrian M Zelazny; Julia A Segre; Evan S Snitkin
Journal:  J Clin Microbiol       Date:  2012-12-19       Impact factor: 5.948

3.  Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis.

Authors:  Gokcen Dinc; Hayati Demiraslan; Ferhan Elmali; Salman Shaheer Ahmed; Gokhan Metan; Emine Alp; Mehmet Doganay
Journal:  Chemotherapy       Date:  2014-02-13       Impact factor: 2.544

Review 4.  Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections.

Authors:  Yen-Hsu Chen; Wen-Chien Ko; Po-Ren Hsueh
Journal:  Expert Opin Pharmacother       Date:  2013-04       Impact factor: 3.889

5.  Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: susceptibility and clinical outcome.

Authors:  Nak-Hyun Kim; Jeong-Hwan Hwang; Kyoung-Ho Song; Pyoeng Gyun Choe; Eu Suk Kim; Sang-Won Park; Hong Bin Kim; Nam Joong Kim; Wan Beom Park; Myoung-Don Oh
Journal:  Scand J Infect Dis       Date:  2012-10-31

6.  Molecular epidemiology and mechanisms of tigecycline resistance in clinical isolates of Acinetobacter baumannii from a Chinese university hospital.

Authors:  Mei Deng; Man-Hua Zhu; Jun-Jie Li; Sheng Bi; Zi-Ke Sheng; Fei-Shu Hu; Jia-Jie Zhang; Wei Chen; Xiao-Wei Xue; Ji-Fang Sheng; Lan-Juan Li
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

7.  In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii.

Authors:  Mao Hagihara; Seth T Housman; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

Review 8.  Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies.

Authors:  Matthew E Falagas; Ioannis A Bliziotis; Ilias I Siempos
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

9.  Effect of proton pump inhibitors on in vitro activity of tigecycline against several common clinical pathogens.

Authors:  Wentao Ni; Xuejiu Cai; Beibei Liang; Yun Cai; Junchang Cui; Rui Wang
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

10.  High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria.

Authors:  Gennaro De Pascale; Luca Montini; Mariano Pennisi; Valentina Bernini; Riccardo Maviglia; Giuseppe Bello; Teresa Spanu; Mario Tumbarello; Massimo Antonelli
Journal:  Crit Care       Date:  2014-05-05       Impact factor: 9.097

View more
  7 in total

1.  A Light-Regulated Type I Pilus Contributes to Acinetobacter baumannii Biofilm, Motility, and Virulence Functions.

Authors:  Cecily R Wood; Emily J Ohneck; Richard E Edelmann; Luis A Actis
Journal:  Infect Immun       Date:  2018-08-22       Impact factor: 3.441

Review 2.  Genetic Regulation of Virulence and Antibiotic Resistance in Acinetobacter baumannii.

Authors:  Carsten Kröger; Stefani C Kary; Kristina Schauer; Andrew D S Cameron
Journal:  Genes (Basel)       Date:  2016-12-28       Impact factor: 4.096

3.  Mechanistic insight into how multidrug resistant Acinetobacter baumannii response regulator AdeR recognizes an intercistronic region.

Authors:  Yurong Wen; Zhenlin Ouyang; Yue Yu; Xiaorong Zhou; Yingmei Pei; Bart Devreese; Paul G Higgins; Fang Zheng
Journal:  Nucleic Acids Res       Date:  2017-09-19       Impact factor: 16.971

Review 4.  Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant A. baumannii: A Review.

Authors:  Jennifer N Lashinsky; Oryan Henig; Jason M Pogue; Keith S Kaye
Journal:  Infect Dis Ther       Date:  2017-03-29

5.  Transcriptome Remodeling of Acinetobacter baumannii during Infection and Treatment.

Authors:  Meredith S Wright; Michael R Jacobs; Robert A Bonomo; Mark D Adams
Journal:  mBio       Date:  2017-03-07       Impact factor: 7.867

Review 6.  Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review.

Authors:  Sajad Yaghoubi; Angelina Olegovna Zekiy; Marcela Krutova; Mehrdad Gholami; Ebrahim Kouhsari; Mohammad Sholeh; Zahra Ghafouri; Farajolah Maleki
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-01-05       Impact factor: 3.267

7.  Genome dynamics of multidrug-resistant Acinetobacter baumannii during infection and treatment.

Authors:  Meredith S Wright; Alina Iovleva; Michael R Jacobs; Robert A Bonomo; Mark D Adams
Journal:  Genome Med       Date:  2016-03-03       Impact factor: 11.117

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.